King's Wealth News | Bocom Intl's research report pointed out that Akeso (09926) has obtained approval for two listing applications, and the commercial product portfolio has been extended to non-oncology areas for the first time. In addition, the company recently announced multiple clinical data at major conferences such as EADV and ESMO.

The bank raised the company's 2024-2026 revenue by 6-10% to reflect the recent approval of new products/new indications and positive clinical progress. The latest DCF target price from 77 HKD has been raised to 87.0 HKD, representing a potential increase of 26% in the next 12 months. Key catalysts include discussions on Kantani and Ivosi medical insurance negotiations, domestic new indication market approval progress, and progress in Ivosi overseas Phase III studies. Maintaining a buy rating.